Carrillo ER, Zavaleta BM, Álvarez AH, Carrillo CDM, Carrillo CCA

Language: Spanish
References: 10
Page: 5-11
PDF size: 198.39 Kb.

ABSTRACT

In the treatment of critically ill patient, antibiotic choice and dosage are influenced by factors related to the pathogen, the drug and the patient's health status. The relationship of pharmacokinetic and pharmacodynamic parameters such as maximum concentration (Cmax), area under the curve (AUC) and minimum inhibitory concentration (MIC) can assist in decision-making to choose the drug and the correct dose. According to these parameters, antibiotics are classified into time-dependent and concentration-dependent. The first ones (betalactams, glycopeptides) could require adjustments in the infusion time; while concentration-dependent ones (aminoglycosides, fluoroquinolones) are based on the Cmax/MIC.

REFERENCES

1. McKinnon PS, Davis S. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis. 2004;23:271-88.

2. Petrosillo N, Drapeau CM, Agrafiotis M, Falagas ME. Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care. Minerva Anestesiol. 2010;76:509-24.

3. Levison ME. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am. 2004;18:451-65.

4. Amsden G. Methodology for the study of pharmacodynamic effects of anti-infective agents En: Mandell: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7° Edición. Philadelphia: Churchill Livingstone; 2009.

5. Roberts AJ, Roberts SM, Semark A, Udy AA, Kirkpatrick MJ, Paterson LD, et al. Antibiotic dosing in the ‘at risk’ critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol. 2011;11:3-10.

6. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of Meropenem 0.5 and 2 g Every 8 Hours as a 3-Hour Infusion Pharmacother. 2003;23:988-91.

7. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of Meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother. 2003;52: 518-21.

8. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the Pharmacodynamics of Meropenem in Patients with Ventilator-Associated Pneumonia following Administration by 3-Hour Infusion or Bolus Injection. Antimicrob Agents Chemother. 2005;49:1337-9.

9. Samtani M, Flamm R, Kaniga K, Nandy P. Pharmacokinetic-Pharmacodynamic-Model-Guided Doripenem Dosing in Critically Ill Patient. Antimicrob Agents Chemother. 2010;54:2360-4.

10. Hyatt JM, Nix DE, Schentag JJ. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother. 1994;38:2730-7.